PerAspera Holdings Ltd. (“PerAspera” or the “Company”) announces Adastra Labs obtains a long-term lease of a 13,035 square foot Township of Langley food manufacturing facility for its cannabis extracts and concentrates operations.  “As an existing food manufacturing site, the facility will require limited alterations.  It goes a long way toward achieving our goal of a Canadian GMP and European EudraLex certified cannabis extractions and concentrates operation that is fully licensed under Health Canada regulations.”

This facility sits on 0.86 Acres in Gloucester Industrial Park in the Township of Langley with an M-2 Industrial Zoning.  Key features of the property include floor drains throughout, extensive cooler/freezer areas, steel clear span construction, and office areas that include a large lunch room, washrooms and changing rooms to facilitate GMP/EudraLex compliance by the workforce.

Further Information

For further information, please contact:

Andy Hale, Managing Director


About PerAspera Holdings Ltd.

In Canada, PerAspera (through its wholly-owned subsidiary, Adastra Labs Inc.) is in the application process to become a Standard Processor under the Cannabis Act administered by Health Canada, with a licence to produce cannabis extracts. These licences will further enable PerAspera and its subsidiaries to produce, package, sell (wholesale), and export medically focused and recreational cannabis extract and concentrate products in Canada to other licenced entities and internationally in jurisdictions where medical cannabis extraction products are legal.

The Company’s operations includes a facility in British Columbia, Canada. The Company is developing its 13,035 square feet facility to be fully devoted to standard processing by early 2019, from which it expects to produce significant amounts of cannabis oil for the Canadian wholesale medical and recreational markets.

The Company will offer a suite of unique products under several existing consumer-focused brands, including tinctures, medicinal oils, concentrates, and when legalized, gel capsules and vaporizer pens. Through acquisition of existing cannabis extraction brands and careful development of its new brands, PerAspera will be positioned to be a leader in branded, commercialized products in both the medical and adult-use markets across North America and internationally.